Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or...
Reexamination Certificate
2006-10-24
2006-10-24
Mosher, Mary E. (Department: 1648)
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
C435S239000, C435S320100, C424S199100, C424S233100, C424S093200
Reexamination Certificate
active
07125706
ABSTRACT:
The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.
REFERENCES:
patent: 4352883 (1982-10-01), Lim
patent: 4725547 (1988-02-01), Sakamoto et al.
patent: 4797368 (1989-01-01), Carter et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5552309 (1996-09-01), March
patent: 5607851 (1997-03-01), Pellegrini et al.
patent: 5744304 (1998-04-01), Munford
patent: 5789244 (1998-08-01), Heidrun et al.
patent: 5837520 (1998-11-01), Shabram et al.
patent: 6143290 (2000-11-01), Zhang et al.
patent: 6168944 (2001-01-01), Condon et al.
patent: 6194210 (2001-02-01), Leu et al.
patent: 6383795 (2002-05-01), Carrion et al.
patent: 6485958 (2002-11-01), Blanche et al.
patent: 6537793 (2003-03-01), Blanche et al.
patent: 6586226 (2003-07-01), Carrion et al.
patent: 6689600 (2004-02-01), Wu et al.
patent: 2002/0018723 (2002-02-01), Mera et al.
patent: 0273085 (1986-12-01), None
patent: 0475623 (1992-03-01), None
patent: 1279843 (1989-11-01), None
patent: 4-9338 (1992-01-01), None
patent: WO 93/18790 (1993-09-01), None
patent: WO 93/25224 (1993-12-01), None
patent: WO 94/06910 (1994-03-01), None
patent: WO 94/17178 (1994-08-01), None
patent: WO 95/06743 (1995-03-01), None
patent: WO 95/10601 (1995-04-01), None
patent: WO 95/19427 (1995-07-01), None
patent: WO 95/25789 (1995-09-01), None
patent: WO 96/09399 (1996-03-01), None
patent: WO 96/27677 (1996-09-01), None
patent: WO 96/32116 (1996-10-01), None
patent: WO 97/04803 (1997-02-01), None
patent: WO 97/08298 (1997-03-01), None
patent: WO/98/00524 (1998-01-01), None
patent: WO 98/22588 (1998-05-01), None
patent: WO 98/26048 (1998-06-01), None
patent: WO 98/35554 (1998-08-01), None
patent: WO 99/12568 (1999-03-01), None
patent: WO 99/41416 (1999-08-01), None
patent: WO 99/54441 (1999-10-01), None
patent: WO 00/32754 (2000-06-01), None
patent: WO 00/34444 (2000-06-01), None
Kotani, “Serum-free production of adenoviral vectors for gene therapy,” Williamsburg BioProcessing Conference, Nov. 18-21, 1996.
Lentfer and Conde, “A rapid and inexpensive procedure for the purification of adenovirions,”Archives of Virology, 56:189-193, 1978.
Lu et al., “Coat protein interactions involved in tobacco mosaic tobamovirus cross-protection,”Virology, 248:188-198, 1998.
Lueckel et al., “Formulations of sugars with amino acids or mannitol—influence of concentration ratio on the properties of the freeze-concentrate and the lyophilizate,”Pharm. Dev. Technol., 3:326-336, 1998.
Montagnon, “Polio and rabies vaccines produced in continuous cell lines: a reality for vero cell line,”Develop. Biol. Standard., 70:27-47, 1989.
Mori et al., “Frequent somatic mutation of theMTSI/CDK4I(Multiple Tumor suppressor/Cyclin dependent Kinase 4 Inhibitor) gene in esophageal squamous cell carcinoma,”Cancer Res., 54:3396-3397, 1994.
Nadeau et al.,Biotechnology and Bioengineering, 51:613-623, 1996.
Payment et al., In:Biotechnology Current Progress, ed. P.N. Cheremisinoff et al., Technomic Publishing, 1991.
Racher et al., “Culture of 293 cells in different culture systems: cell growth and recombinant adenovirus production,”Biotechnology Techniques, 9:169-174, 1995.
Sagrera et al., “Study of the influence of salt concentration on Newcastle disease virus matrix protein aggregation,”Biochem. Mol. Biol. Int., 46:429-435, 1998.
Trepanier et al.,Journal of Virological Methods, 3:201-211, 1981.
Vanlandschoot et al., “pH-dependent aggregation and secretion of soluble monomeric influenza hemagglutinin,”Arch. Virol., 143:227-239, 1998.
Vossen and Fried, “Sequestration stabilizes lac repressor-DNA complexes during gel electrophoresis,”Anal. Biochem., 245:85-92, 1997.
Wills and Menzel, “Adenovirus Vectors for Gene Therapy of Cancer,”J. of Cellular Biochem., Suppl: 17E, S216:206, 1993.
Aboud et al., “Rapid purification of extracellular and intracellular moloney murine leukemia virus,”Arch. Virol., 71:185-195, 1982.
Arap et al., “Replacement of thep16/CDKN2gene suppresses human glioma growth,”Cancer Res., 55:1351-1354, 1995.
Baichwal and Sugden,In: Kucherlapati R, ed. Gene transfer. New York: Plenum Press, pp. 117-148, 1986.
Cartwright, T.,Animal cells as bioreactors, In: Cambridge Studies in Biotechnology, Cambridge University Press, No. 11:58-63, 1994.
Benvenisty and Neshif, “Direction introduction of genes into rats and expression of the genes,”Proc. Nat'l Acad. Sci. USA, 83:9551-9555, 1986.
Berg et al., “High-level expression of secreted proteins from cells adapted to serum-free suspension culture,”BioTechniques, 14(6):972-978, 1993.
Bett, “An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3,”Proc. Natl. Acad. Sci. USA, 91(19):8802-8806, 1994.
Bussemakers et al., “Decreased expression of E-cadherin in the progression of rat prostatic cancer,”Cancer Res., 52:2916-2922, 1992.
Caldas et al., “Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma,”Nat. Genet., 8:27-32, 1994.
Casey et al., “Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene,”Oncogene, 6:1791-1797, 1991.
Chen and Okayama, “High-efficiency transfection of mammalian cells by plasmid DNA,”Mol. Cell Biol., 7:2745-2752, 1987.
Cheng et al., “p16Alterations and deletion mapping of 9p21-p22 in malignant mesothelioma,” CancerRes., 54:5547-5551, 1994.
Cheung et al., “Structure and function of C-CAM1,”J Biol Chem. 268(32):24303-24310, 1993.
Cheung et al., “The cytoplaxmic domain of C-CAM is required for C-CAM-mediated adhesion function: studies of a C-CAM transcript containing an unspliced intron”,Biochem. J., 295:427-435, 1993.
Cheung et al., “Cell-CAM105 isoforms with different adhesion functions are coexpressed in adult rat tissues and during liver development”,J. Biol. Chem., 268:6139-6146, 1993.
Coffin, “Retroviridae and their replication,”In: Virology, Fields et al. (eds.), New York: Raven Press, pp. 1437-1500, 1990.
Coupar et al., “A general method for the construction of recombinant vaccinia virus expressing multiple foreign genes,”Gene, 68:1-10, 1988.
Crooks et al., “Purification and analysis of infections virions and native non-structural antigens from cells infected with tick-borne encephalitis virus,”J. Chrom., 502:59-68, 1990.
Dubensky et al,. “Direct transfection of viral and plasmid DNA into the liver or spleen of mice,”Proc. Nat. Acad. Sci. USA, 81:7529-7533, 1984.
Edelman and Crossin, “Cell adhesion molecules: implications for a molecular histology,”Annu. Rev. Biochem., 60:155-190, 1991.
Edelman, “Cell adhesion and the molecular processes of morphogenesis,”Annu. Rev. Biochem., 54:135-169, 1985.
Fechheimer et al., “Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading,”Proc. Nat'l Acad. Sci. USA, 84:8463-8467, 1987.
Ferkol et al., “Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced into the livers of adult rats by receptor-mediated gene transfer,”FASEB J., 7:1081-109
Cho Toohyon
Gallagher Shawn
Thwin Capucine
Wu Zheng
Zhang Shuyuan
Fulbright & Jaworski L.L.P.
Introgen Therapeutics Inc.
Mosher Mary E.
LandOfFree
Method for the production and purification of adenoviral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the production and purification of adenoviral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the production and purification of adenoviral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3645032